Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight
Comunicato Precedente
Comunicato Successivo
Key Takeaways from the Dry Eye Disease Market Report
Discover which therapies are expected to grab the major dry eye disease market share @ Dry Eye Disease Market Report
Dry Eye Disease Overview
Dry eye disease (DED) is a common chronic condition characterized by inadequate tear production or excessive tear evaporation, leading to inflammation and damage to the eye's surface. Causes of DED are multifactorial and include aging, hormonal changes, prolonged screen use, environmental factors (dry climates, wind), certain medications, autoimmune conditions, and contact lens wear. Symptoms often include persistent dryness, redness, irritation, a gritty or sandy sensation, sensitivity to light, blurry vision, and in some cases, paradoxical excessive tearing.
Diagnosing DED typically involves a thorough eye examination by an ophthalmologist or optometrist. Common diagnostic tests include the Schirmer test, tear breakup time, and ocular surface staining with dyes such as fluorescein or lissamine green to detect surface damage. Early diagnosis and management are essential to prevent complications like corneal damage and vision impairment.
Dry Eye Disease Epidemiology Segmentation
The dry eye disease epidemiology section provides insights into the historical and current dry eye disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The dry eye disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Dry Eye Disease Treatment Market
Pharmacological treatments play a pivotal role in the comprehensive management of dry eye disease. Common solutions like artificial tears provide quick relief by enhancing the tear film, while prescription medications such as cyclosporine (e.g., RESTASIS) and lifitegrast (e.g., XIIDRA) help alleviate symptoms through their anti-inflammatory effects. Recently approved therapies, including VEVYE (cyclosporine ophthalmic solution)/CyclASol and MIEBO (NOV03), offer new and promising options.
Beyond pharmacological approaches, other strategies for managing DED include in-office treatments like intense pulsed light therapy and meibomian gland expression, as well as eyelid care techniques such as warm compresses and lid scrubs. For more severe cases, lifestyle changes, punctal plugs, or scleral contact lenses may be considered to provide additional symptom relief.
The eye drop market is largely focused on alleviating dry eye symptoms using moisturizing agents such as hyaluronic acid. However, there is a notable gap in effective treatments for viral keratoconjunctivitis, a condition often mismanaged with antibiotics. Marinomed Biotech AG's MAM-1001-3 eye drops aim to address this need by leveraging Carragelose, a red seaweed-derived polymer with exceptional moisturizing and broad-spectrum antiviral properties.
Classified as a medical device and in the pre-launch phase with MDD certification, MAM-1001-3 provides dual benefits: soothing dry, irritated eyes and potentially offering a targeted solution for viral keratoconjunctivitis, thereby advancing patient care in ocular health. In summary, implementing a personalized combination of these management strategies can effectively reduce symptoms and enhance the quality of life for individuals with DED.
To know more about dry eye disease treatment guidelines, visit @ Dry Eye Disease Management
Dry Eye Disease Pipeline Therapies and Key Companies
Discover more about dry eye disease drugs in development @ Dry Eye Disease Clinical Trials
Dry Eye Disease Market Dynamics
The dry eye disease market dynamics are expected to change in the coming years. Dry eye is a highly prevalent condition, especially among the aging population, creating a substantial need for effective diagnosis, treatment, and management solutions. Current treatment options, such as artificial tears, prescription drugs, eyelid hygiene products, and punctal plugs, enable tailored approaches to address the condition. Increased public education campaigns can raise awareness and encourage individuals to seek help, while collaboration among pharmaceutical companies, research institutions, and healthcare providers can drive the development of novel therapies and diagnostic tools for dry eye disease.
Furthermore, potential therapies are being investigated for the treatment of dry eye disease, and it is safe to predict that the treatment space will significantly impact the dry eye disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the dry eye disease market in the 7MM.
However, several factors may impede the growth of the dry eye disease market. Some dry eye treatments, particularly prescription medications, can cause side effects like blurred vision or itching, while the cost of treatment, including medications and frequent healthcare visits, can be burdensome for patients; additionally, intense market competition increases pricing pressures and marketing expenditures for companies, and failure to properly diagnose or treat dry eye may lead to disease progression and complications, significantly impacting patient health and well-being.
![Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight](https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg)
Moreover, dry eye disease treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, dry eye disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact dry eye disease market growth.
Scope of the Dry Eye Disease Market Report
Download the report to understand which factors are driving dry eye disease market trends @ Dry Eye Disease Market Trends
Table of Contents
Related Reports
Dry Eye Disease Epidemiology Forecast
Dry Eye Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the dry eye disease epidemiology trends.
Dry Eye Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dry eye disease companies, including Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine, among others.
Glaucoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glaucoma companies, including Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, among others.
Glaucoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glaucoma companies, including Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision, HK inno.N, Avirmax Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
View original content:https://www.prnewswire.co.uk/news-releases/dry-eye-disease-market-to-observe-stupendous-growth-by-2034--delveinsight-302361478.html
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN05888&Transmission_Id=202501281731PR_NEWS_EURO_ND__EN05888&DateId=20250128)
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom